Making sustainable medicines through eco-design
Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Search
Making more health through animal health
Boehringer Ingelheim and Ashoka aim to build a world with a greater access to health for people, animals and their communities.
In-Reach Africa initiatives successfully completed
We are proud to report the successful completion of Kuza Afya and Tiba Yako, two of our In-Reach Africa initiatives.
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Transforming Science Day
How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
Reimagining digital healthcare worldwide
How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Why is Diversity, Equity and Inclusion important to us?
Why is Diversity, Equity and Inclusion important to us?
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Full data chronic kidney disease trial efficacy
Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
Imagine: Ecological stoves safeguard family health in Mexico
With Fondo Para la Paz, we’ve developed ecological stoves for safer indoor cooking, enhancing respiratory health for rural Mexican families
Boosting performance with an inclusive performance culture
Boosting performance of organizations with an inclusive performance culture
Helping smallholder farmers after Covid-19
In Ghana, we are helping smallholder farmers overcome hardship caused by the pandemic.
International Women's Day
We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
Innovation from within
Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Generalized pustular psoriasis: Unmet needs
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Social innovation: catalyst for sustainable health solutions
Supporting social innovators drives sustainable health solutions in underserved communities. Learn more about Boehringer Ingelheim Social Engagements.
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Improving Access to Healthcare
According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
Algorithms to battle heartworm disease
Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Anna Race
Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.
Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim
Tour our Large Scale Cell Culture Facility in Vienna, Austria, advancing biopharmaceutical production with cutting-edge cell culture technology.
Work life balance
It's important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.